Major indices delivered a mixed performance on Friday as the blue-chip Dow Jones turned in its seventh-consecutive losing ...

Shares of Biogen Inc. BIIB shed 3.41% to $150.03 Friday, on what proved to be an all-around mixed trading session for the ...

Wall Street trading got off to a mixed start on Friday after the blue-chip Dow Jones turned in its sixth-consecutive losing session a day earlier.

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Integrated Wealth Concepts LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 61.3% during the third ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Biogen Inc. closed $112.97 below its 52-week high ($268.30), which the company achieved on January 3rd.

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...

Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple ...